LY3938577

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 1 Diabetes MellitusDiabetes Mellitus, Type 2

67 competitors in Type 1 Diabetes Mellitus

#DrugCompanyPhaseTrials

1

Actos

Takeda

Approved

22

Mounjaro

Eli Lilly

Approved

13

Ozempic

Novo Nordisk

Approved

—4

Brethine

Sanofi

Approved

—5

Diabeta

Pfizer

Approved

—6

Rocaltrol

Jazz Pharmaceuticals

Approved

—7

Neoral

Novartis

Approved

—8

Opzelura

Pfizer

Approved

—9

Calciferol

Jazz Pharmaceuticals

Approved

—10

Cellcept

Roche

Approved

—Show 42 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus1 trial

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Completed·Eli Lilly·Phase 1·NCT06132126·66 enrolled

Type 1 Diabetes Mellitus1 trial

A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

Recruiting·Eli Lilly·Phase 1·NCT06280703·118 enrolled

Diabetes Mellitus, Type 21 trial

A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

Active, not recruiting·Eli Lilly·Phase 2·NCT07215312·100 enrolled

Details

Drug Info

Related News